Targovax’s Chair of the Board, Jonás Einarsson, is interviewed by Dagens Medisin regarding promising 1-year overall survival data when combining TG01 with gemcitabine (chemotherapy) as supplementary treatment of patients with pancreatic cancer.
Read the article (in Norwegian) here: dagensmedisin.no/artikler/2016/03/11/melder-om-gode-resultater-for-norskutviklet-kreftvaksine